Janus kinase (JAK) inhibitors are an important treatment option for people with chronic inflammatory diseases such as ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Filgotinib, a Janus Kinase 1 inhibitor, remains well-tolerated for up to 8 years with consistent efficacy in patients with ...

Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...

Why do medications that are supposed to help patients with chronic inflammatory diseases sometimes lead to blood clots? This is one of the questions that a team of researchers from Aarhus University ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses o ...

Patients with atopic dermatitis were at greater risk for serious infection after initiating Janus kinase inhibitors vs Th2 cytokine inhibitors.

HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...

Filgotinib maintained a favorable safety and efficacy profile for up to 8 years among patients with RA who participated in the DARWIN 3 LTE.